NorthWest Biotherapeutics Inc (NWBO)

[GermanCol]

Firms usually begin the process of obtaining a nonproprietary name by filing a submission with the USAN Program or the WHO when a drug is in phase I or phase II clinical trials. Most prefer to complete generic name assignments by the time they are ready to publish papers about the drug so that they can use the name instead of a manufacturer code in publications. The USAN must be assigned before conducting premarketing labeling negotiations with the FDA.

https://journalofethics.ama-assn.org/article/how-do-drugs-get-named/2019-08